Can Tesamorelin cause long-term problems

QUICK ANSWER: Research indicates some long-term concerns including glucose metabolism changes, fluid retention, and cardiovascular markers. Most documented effects resolve after discontinuation, though extended safety data beyond two years remains limited.

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been the subject of considerable scientific interest since its initial clinical development in the early 2000s. Approved by the United States Food and Drug Administration in 2010 for a specific medical indication — the reduction of excess visceral abdominal fat in HIV-infected adults with lipodystrophy — it has since attracted attention from researchers studying its broader metabolic and neuroendocrine effects. As with any compound that influences the growth hormone axis, a central question in the literature concerns what happens over extended periods of use: does Tesamorelin cause long-term problems, and if so, what does the published evidence actually say? This blog examines that question through the lens of peer-reviewed clinical research. It explores the mechanism of action, the documented short- and long-term effects observed in trials, the specific safety signals that have emerged in extended studies, and the areas where scientific uncertainty remains. All content is grounded in published clinical evidence and is intended for informational purposes only.

What Is Tesamorelin and How Does It Work?

The GHRH Analogue Mechanism Explained

To evaluate whether Tesamorelin causes long-term problems, it is essential to first understand the biological mechanism through which it operates. Tesamorelin is a stabilised, full-sequence analogue of human growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide responsible for stimulating the pituitary gland to produce and secrete growth hormone (GH). Unlike exogenous growth hormone, which directly raises GH levels, Tesamorelin acts upstream — stimulating the pituitary in a pulsatile, physiologically regulated manner. [1]

This distinction matters because pulsatile GH release is the natural pattern in the human body. Direct GH administration bypasses this regulation entirely, whereas GHRH analogues like Tesamorelin preserve the feedback inhibition provided by somatostatin, the endogenous GH-suppressing hormone. This means the pituitary retains some capacity to self-regulate, which theoretically limits the ceiling of GH stimulation and may reduce some risks associated with unregulated GH excess. [1]

How Tesamorelin Affects IGF-1 and Visceral Fat

Once GH is released in response to Tesamorelin, it stimulates the liver to produce insulin-like growth factor-1 (IGF-1), the primary mediator of growth hormone’s anabolic and lipolytic effects. IGF-1 promotes fat mobilisation from adipose tissue, particularly visceral adipose tissue — the metabolically active fat depot surrounding the abdominal organs. In clinical trials, this mechanism produced statistically significant reductions in visceral adipose tissue (VAT) in treated populations. [2]

However, elevated IGF-1 also has downstream consequences that are relevant to long-term safety. IGF-1 is a potent growth factor with mitogenic properties — meaning it promotes cell growth and division. The implications of sustained IGF-1 elevation for cancer risk, glucose metabolism, and cardiovascular physiology have been among the most closely studied aspects of extended Tesamorelin research. [2]

Tesamorelin Side Effects: What Short-Term Trials Documented

Phase 3 Trial Safety Data: The LIPO-010 and LIPO-011 Studies

The foundational safety data for Tesamorelin comes from the Phase 3 LIPO-010 and LIPO-011 trials, which enrolled HIV-positive adults with lipodystrophy and assessed both efficacy and safety over 26-week primary treatment periods with optional 26-week extensions. These trials established the core short-term side effect profile that now appears on regulatory documentation. [3]

The most commonly reported adverse events in these trials were injection site reactions, including erythema, pruritus, pain, and urticaria at the local site. Systemic adverse events included peripheral oedema, arthralgia (joint pain), myalgia, and paraesthesia — all of which are consistent with the known physiological effects of elevated growth hormone levels on fluid balance and soft tissue. These side effects were generally mild to moderate in severity and manageable within the trial context. [3]

Fluid Retention and Growth Hormone-Related Adverse Effects

Growth hormone is well-documented to promote sodium and water retention through its effects on the renal tubules. In Tesamorelin trials, peripheral oedema — the clinical manifestation of this fluid retention — was reported at higher rates in treated groups than in placebo groups. While this effect was not severe in most participants, it represents a meaningful consideration in populations with pre-existing cardiovascular or renal conditions, where excess fluid retention can have compounding consequences. [3]

Arthralgia and carpal tunnel syndrome, both associated with GH excess states, were also observed. Carpal tunnel syndrome — caused by fluid accumulation in the narrow carpal tunnel of the wrist compressing the median nerve — has been documented in acromegaly (the condition caused by chronic GH excess) and appeared as an adverse event in Tesamorelin trials, though at relatively low rates. The clinical significance of this observation increases with the duration of exposure. [4]

Tesamorelin and Glucose Metabolism: Long-Term Diabetes Risk

How Growth Hormone Affects Insulin Sensitivity

One of the most clinically significant long-term concerns identified in Tesamorelin research involves its effects on glucose metabolism. Growth hormone is a counter-regulatory hormone to insulin — meaning it opposes insulin’s action and promotes a state of relative insulin resistance. Chronic elevation of GH, or sustained stimulation of GH release, therefore carries an inherent risk of impairing glucose tolerance and potentially precipitating or worsening type 2 diabetes mellitus. [5]

In the LIPO-010 and LIPO-011 trials, fasting glucose and insulin levels were monitored as secondary safety endpoints. The data showed that Tesamorelin was associated with modest but statistically significant increases in fasting blood glucose and insulin resistance markers compared with placebo. Importantly, in the HIV-lipodystrophy population studied — where metabolic dysregulation is already prevalent due to antiretroviral therapy — these changes represented a meaningful additional metabolic burden. [5]

Tesamorelin Diabetes Risk: What Extended Follow-Up Shows

The Tesamorelin diabetes risk signal became more prominent when researchers examined extended follow-up data. A 2014 analysis of participants from the Phase 3 extension studies found that those with pre-existing glucose dysregulation at baseline were more likely to experience further deterioration in glucose tolerance during treatment. The incidence of new-onset diabetes, while not dramatically elevated, was numerically higher in the treated group than in the placebo group in extended cohorts. [5]

These findings have practical implications. The prescribing information for Tesamorelin includes a warning regarding glucose intolerance and diabetes, recommending monitoring of blood glucose in all treated individuals. Current research suggests that this risk is most pronounced in individuals who already have impaired fasting glucose or impaired glucose tolerance prior to treatment initiation, making baseline metabolic assessment a critical component of pre-treatment evaluation in clinical settings. [5]

Does Glucose Dysregulation Reverse After Stopping?

An important nuance in the long-term glucose data concerns reversibility. Published discontinuation studies suggest that the glucose-raising effects of Tesamorelin largely reverse after the compound is stopped, with fasting glucose and insulin levels returning toward baseline values within weeks of discontinuation. However, in individuals with pre-existing metabolic vulnerability, the acceleration of glucose dysregulation during treatment may represent a window of increased risk that does not fully normalise upon cessation. [6]

Tesamorelin IGF-1 Elevation: Cancer Risk Research

The IGF-1 and Cancer Relationship in Oncology Literature

Elevated IGF-1 levels have been studied extensively in the context of cancer biology. Epidemiological and mechanistic research has documented associations between higher circulating IGF-1 and increased risk of certain cancers, including colorectal, breast, and prostate malignancies. The biological rationale is well-established: IGF-1 promotes cellular proliferation, inhibits apoptosis (programmed cell death), and supports tumour angiogenesis — all mechanisms that could theoretically facilitate cancer development or progression. [7]

Because Tesamorelin reliably raises IGF-1 levels — indeed, this elevation is part of its intended mechanism — the question of whether sustained IGF-1 elevation translates to a clinically meaningful cancer risk in treated populations is one of the most scrutinised aspects of its long-term safety profile. The published trials were not designed or powered to detect differences in cancer incidence, which means definitive conclusions cannot yet be drawn from existing data. [7]

What Current Evidence Says About Tesamorelin and Malignancy

The LIPO-010 and LIPO-011 trials, along with their extension periods, did not identify a statistically significant increase in cancer incidence in the Tesamorelin group compared with placebo. However, the follow-up periods in these trials — typically one to two years — are insufficient to detect carcinogenic effects, which often manifest over decades. The regulatory agencies that approved Tesamorelin have noted this limitation and classified IGF-1 elevation as a potential long-term risk requiring post-marketing surveillance. [8]

Critically, the prescribing information contraindicates Tesamorelin in patients with active malignancies. This precaution reflects the mechanistic concern rather than proven causation: in the presence of an established cancer, the mitogenic properties of elevated IGF-1 could theoretically accelerate tumour growth. This contraindication is consistent with the broader precautionary approach applied to all GH-axis-stimulating compounds in oncology contexts. [8]

IGF-1 Monitoring as a Long-Term Safety Strategy

Given the theoretical cancer risk, clinical protocols for Tesamorelin use include periodic measurement of serum IGF-1 levels. If IGF-1 rises substantially above the age- and sex-adjusted reference range — suggesting supraphysiological stimulation of the GH axis — clinical guidelines recommend reassessment of continued use. This monitoring framework represents the current evidence-based approach to managing the Tesamorelin IGF-1 elevation concern in practice. [8]

Tesamorelin Cardiovascular Effects: Research Evidence

Lipid Changes and Cardiometabolic Markers

Tesamorelin’s primary clinical effect — reduction of visceral adipose tissue — has potential cardiovascular implications, both positive and negative. On the positive side, visceral fat is a recognised contributor to systemic inflammation, dyslipidaemia, and insulin resistance, and its reduction should theoretically improve cardiometabolic risk. In the Phase 3 trials, Tesamorelin-treated participants showed reductions in triglycerides and improvements in the waist-to-hip ratio, both of which are markers of cardiovascular risk. [9]

However, the growth hormone axis has complex effects on lipid metabolism that are not uniformly cardioprotective. GH and IGF-1 stimulate lipolysis, which releases free fatty acids into the circulation. Sustained free fatty acid elevation can have adverse effects on endothelial function and hepatic lipid metabolism, potentially counteracting some of the benefits of visceral fat reduction. The net cardiovascular effect of Tesamorelin over extended periods has not been definitively characterised in outcomes-level data. [9]

Blood Pressure and Fluid Balance Effects Over Time

The fluid-retaining effects of growth hormone stimulation have implications for blood pressure over time. In individuals with hypertension or borderline blood pressure elevation, the sodium and water retention caused by GH and IGF-1 can meaningfully increase blood pressure. Published trial data showed modest increases in systolic blood pressure in some subgroups of Tesamorelin-treated participants, though the magnitude was not sufficient to reach statistical significance in the primary analyses. [4]

These Tesamorelin cardiovascular effects were generally reversible upon discontinuation, consistent with the known reversibility of GH-related fluid retention. However, in longer theoretical exposure scenarios — particularly in individuals with pre-existing hypertension or renal impairment — the cumulative burden of even modest blood pressure elevation could contribute to adverse cardiovascular outcomes over years. This remains an area where long-term observational data would substantially inform clinical decision-making. [4]

Tesamorelin Long-Term Effects on the Pituitary and HPA Axis

Does Tesamorelin Suppress Natural GHRH Production?

A question that arises in research on GHRH analogues concerns the potential for long-term exogenous stimulation to suppress endogenous GHRH production — a phenomenon known as feedback inhibition or desensitisation. If sustained Tesamorelin exposure causes the hypothalamus to reduce its own GHRH output, the pituitary’s responsiveness to endogenous signals could be attenuated over time. [10]

The published data on this question is nuanced. Short-term studies have not demonstrated clinically significant suppression of endogenous GHRH function, partly because Tesamorelin’s mechanism preserves the somatostatin feedback loop. However, the available data extends only to approximately two years of continuous use in the best-documented cohorts. Whether longer exposure — beyond the studied timeframes — produces neuroendocrine adaptation that persists after discontinuation is not yet definitively answered by the literature. [10]

Antibody Formation and Loss of Efficacy Over Time

Another documented Tesamorelin long-term effect involves the development of anti-Tesamorelin antibodies. In the Phase 3 trials, a proportion of participants developed antibodies against Tesamorelin over the course of treatment. In most cases, these antibodies were not neutralising — meaning they did not interfere with the compound’s activity — and did not cause adverse immune reactions. [3]

However, a subset of participants developed neutralising antibodies that were associated with attenuated efficacy over time. This finding has practical implications for long-term use: some individuals may experience a gradual reduction in the visceral fat-reducing effect of Tesamorelin over months or years as antibody titres rise. The immunogenic potential of the compound is therefore another dimension of its long-term safety and efficacy profile that warrants monitoring. [3]

Tesamorelin Cognitive Effects: Emerging Research in Neurological Health

Tesamorelin and Cognitive Function in Older Adults

An intriguing and relatively recent body of research has examined the effects of the growth hormone axis on brain health and cognitive function. GH and IGF-1 receptors are present in multiple brain regions, including the hippocampus and prefrontal cortex, and there is mechanistic evidence that these hormones support neurogenesis, synaptic plasticity, and white matter integrity. Against this background, researchers have investigated whether Tesamorelin might have beneficial or detrimental cognitive effects with extended use. [11]

A notable clinical trial published in 2017 by Baker and colleagues investigated Tesamorelin’s effects on cognitive function in older adults with mild cognitive impairment over six months. The study found that Tesamorelin-treated participants showed improvements in executive function and verbal memory compared with placebo. These cognitive effects were associated with IGF-1 elevations and reductions in abdominal adiposity, suggesting that improved metabolic health may mediate some of the brain-related effects. [11]

Is There a Long-Term Cognitive Risk From IGF-1 Elevation?

While the short-term cognitive data is generally favourable, the long-term neurological implications of sustained IGF-1 elevation require consideration. Very high IGF-1 levels — as seen in acromegaly — are associated with increased risk of cerebrovascular disease, polyneuropathy, and structural brain changes. Whether the more modest IGF-1 elevations produced by Tesamorelin produce analogous risks over extended periods is not yet established by clinical evidence, but the theoretical concern has been noted in review literature. [12]

The current consensus in the research community is that the short-term cognitive data is encouraging, particularly in populations where GH axis function has declined with age, but that claims about long-term neuroprotective benefits must await longer follow-up studies. The existing trials are informative but insufficient to definitively resolve whether cognitive gains persist, plateau, or reverse beyond six to twelve months. [12]

What Happens When Tesamorelin Treatment Is Discontinued?

Visceral Fat Regain After Stopping: What the Evidence Shows

One of the most clinically meaningful findings in the Tesamorelin literature concerns what happens when treatment is discontinued. The Phase 3 extension trials included a treatment-interruption phase in which participants who had achieved VAT reduction were randomised to continue or switch to placebo. The data from this phase showed that visceral fat regained lost ground relatively quickly after stopping — with a meaningful proportion of the treatment-achieved VAT reduction reversed within six months of discontinuation. [13]

This finding has significant implications for the conceptualisation of Tesamorelin as a long-term therapy. If the primary clinical benefit — visceral fat reduction — reverses upon cessation, then the risk-benefit calculation must account for the cumulative exposure required to maintain that benefit indefinitely. Whether the risks identified in short-term trials compound proportionally with extended exposure is a central unanswered question in the long-term safety literature. [13]

Hormonal Normalisation After Discontinuation

The hormonal changes induced by Tesamorelin — including elevated GH pulse amplitude, raised IGF-1, and modest changes in fasting glucose — generally normalise within weeks of stopping treatment. This reversibility is consistent with the pulsatile, physiologically regulated mechanism of action and represents a meaningful safety advantage over direct exogenous GH administration. The pituitary’s capacity to respond to endogenous GHRH appears to recover promptly after Tesamorelin is withdrawn in the majority of studied participants. [6]

Tesamorelin Safety in Specific Populations: Who Is at Greater Risk?

HIV-Positive Individuals on Antiretroviral Therapy

The population in which Tesamorelin is most comprehensively studied is HIV-positive individuals receiving antiretroviral therapy (ART) who have developed lipodystrophy — a condition characterised by redistribution of body fat, including visceral fat accumulation. This population already carries an elevated baseline risk of metabolic syndrome, insulin resistance, and cardiovascular disease due to both the direct effects of HIV infection on metabolism and the adverse metabolic profiles of certain antiretroviral agents. [2]

In this context, the glucose-raising and fluid-retaining effects of Tesamorelin add to an already complex metabolic picture. Research has highlighted the importance of particularly careful monitoring in this group, with attention to emerging glucose dysregulation and blood pressure changes throughout the duration of treatment. The net benefit-risk calculation in this population has been deemed favourable by regulatory agencies for the specific indication of HIV-related lipodystrophy, but the underlying metabolic fragility means the margin is narrower than in metabolically healthy populations. [2]

Older Adults and Age-Related Risk Considerations

In older adult populations, who are among the groups studied for potential cognitive and metabolic applications of Tesamorelin, several age-specific risk factors warrant consideration. The prevalence of glucose intolerance, hypertension, renal impairment, and subclinical malignancy all increases with age, meaning that each of the long-term risk domains identified in younger trial populations may be amplified in older individuals. [11]

Additionally, the pharmacodynamic response to Tesamorelin changes with age. GH secretion naturally declines with advancing years — a process known as somatopause — and the pituitary’s responsiveness to GHRH stimulation is attenuated in older adults. This means that equivalent stimulation may produce a different magnitude of GH and IGF-1 elevation in older individuals compared with younger ones, further complicating generalisation from the primary HIV-lipodystrophy trial cohorts. [11]

Tesamorelin Contraindications and Known Risk Factors

Absolute Contraindications Identified in Clinical Research

The clinical research and regulatory literature identifies several absolute contraindications to Tesamorelin use that are directly relevant to long-term safety. Active malignancy — whether pre-existing or newly diagnosed during treatment — is a primary contraindication, given the mitogenic properties of elevated IGF-1 discussed earlier. Pituitary pathology, including pituitary tumours or prior pituitary irradiation, is also contraindicated, as these conditions can alter the response to GHRH stimulation unpredictably. [8]

Pregnancy is another absolute contraindication, as the effects of Tesamorelin on foetal development have not been adequately studied and the potential for harm to the developing foetus via IGF-1-mediated growth factor activity represents an unacceptable theoretical risk. These Tesamorelin contraindications are consistent across the major regulatory jurisdictions in which the compound has been evaluated. [8]

Relative Contraindications and High-Risk Contexts

Relative contraindications — situations where use requires particularly careful risk-benefit assessment — include pre-existing diabetes or impaired glucose tolerance, significant cardiovascular disease, and chronic oedematous conditions. Each of these represents a clinical context where the known adverse effects of growth hormone stimulation are more likely to produce clinically meaningful harm. The research literature consistently highlights these populations as requiring heightened vigilance if treatment is considered. [5]

Gaps in the Long-Term Safety Evidence for Tesamorelin

The Two-Year Evidence Ceiling and What It Means

Perhaps the most honest and important statement that can be made about Tesamorelin long-term problems is that the published clinical trial evidence does not extend beyond approximately two years of continuous use in any well-controlled cohort. The approved indication — HIV-related lipodystrophy — was based on 26-week primary trials with 26-week extensions, and the real-world use data that has accumulated since 2010 has not been systematically compiled into peer-reviewed long-term safety analyses. [14]

This evidence ceiling means that questions about cancer risk over a decade of use, cumulative cardiovascular effects, or very long-term pituitary function cannot be answered with confidence by the existing literature. Researchers and clinicians working in this area consistently call for larger, longer post-marketing observational studies to address these gaps. Until that data exists, the long-term safety profile of Tesamorelin must be characterised as incompletely understood rather than definitively safe or unsafe. [14]

Comparison With Growth Hormone: What Acromegaly Research Teaches Us

In the absence of long-term Tesamorelin-specific data, researchers have drawn on the extensive literature surrounding acromegaly — the disease state caused by chronic, unregulated GH excess — and exogenous GH replacement therapy to inform risk extrapolation. Acromegaly is associated with substantially elevated rates of cardiovascular disease, diabetes, colonic polyps and colorectal cancer, sleep apnoea, and arthropathy. However, the GH elevations in acromegaly are typically far greater in magnitude and completely unregulated compared with the modest, feedback-preserved GH stimulation produced by Tesamorelin. [15]

Exogenous GH replacement therapy studies, conducted over longer periods in GH-deficient adults, provide a more relevant reference point. This literature generally shows acceptable long-term safety at physiological replacement levels, though with acknowledged increased rates of glucose intolerance. Whether Tesamorelin’s effects on long-term disease risk more closely resemble acromegaly, GH replacement, or something in between remains an open question in the research community. [15]

Final Thoughts

The clinical research on whether Tesamorelin causes long-term problems reveals a nuanced picture that resists a simple yes or no answer. The compound has a well-characterised short-term adverse event profile dominated by injection site reactions, fluid retention, joint discomfort, and modest elevations in fasting glucose — effects that are physiologically consistent with growth hormone axis stimulation and that are largely reversible upon discontinuation. The more concerning long-term signals involve glucose dysregulation in metabolically vulnerable individuals, the theoretical carcinogenic implications of sustained IGF-1 elevation, and cardiovascular effects that may compound in individuals with pre-existing risk factors.

What makes a definitive assessment difficult is the two-year ceiling on the best-quality clinical evidence. The questions that matter most from a long-term safety standpoint — cancer incidence, cardiovascular outcomes over a decade, and sustained neuroendocrine effects — require follow-up periods that the existing trial literature simply does not yet provide. This is not a unique challenge for Tesamorelin; it reflects a broader limitation in how pharmaceutical compounds are studied and approved, where the evidence base at the time of regulatory clearance is necessarily limited to what could be gathered in a reasonable pre-approval timeframe.

For researchers, clinicians, and those tracking developments in peptide science, resources such as Peptides Lab UK provide access to current scientific literature and product information relevant to the evolving landscape of peptide research. As the field matures and longer-term observational data accumulates, the safety characterisation of Tesamorelin will inevitably become more precise. Until then, the most scientifically defensible position is one of informed caution: recognising the documented short-term risks, acknowledging the theoretical long-term concerns, and advocating for the extended post-marketing surveillance studies that are necessary to answer the remaining questions with confidence.

Frequently Asked Questions

1. Is Tesamorelin safe for long-term use?

Clinical trials extend to approximately two years — beyond this, definitive long-term safety data is limited. Documented concerns include glucose intolerance, IGF-1 elevation, and fluid retention. Regulatory bodies classify it as acceptable for its approved indication with ongoing monitoring.

2. What are the main side effects of Tesamorelin?

The most common documented side effects are injection site reactions (redness, itching, pain), peripheral oedema, joint pain (arthralgia), muscle aches, and paraesthesia. These are consistent with elevated growth hormone levels and generally resolve after discontinuation.

3. Does Tesamorelin raise blood sugar levels?

Yes. Clinical trials show Tesamorelin causes modest but statistically significant increases in fasting glucose and insulin resistance markers, particularly in individuals with pre-existing metabolic vulnerabilities. Glucose monitoring is recommended throughout treatment.

4. Can Tesamorelin increase cancer risk?

Elevated IGF-1 — which Tesamorelin reliably raises — is theoretically associated with cancer promotion. Trials to date have not shown a statistically significant increase in cancer incidence, but follow-up periods are too short to rule out long-term risk. Tesamorelin is contraindicated in active malignancy.

5. What happens when you stop Tesamorelin?

Visceral fat substantially regains within six months of discontinuation. Hormonal changes — including elevated GH, IGF-1, and fasting glucose — largely normalise within weeks of stopping. The reversibility of effects is considered a key safety advantage of GHRH analogues over direct GH administration.

6. Does Tesamorelin affect cognitive function?

A 2017 clinical trial found Tesamorelin improved executive function and verbal memory in older adults with mild cognitive impairment over six months. Whether these benefits persist long-term is not yet established. Very high IGF-1 levels carry neurological risks, though modest elevations from Tesamorelin are far below acromegalic ranges.

7. Who should not use Tesamorelin?

Absolute contraindications include active malignancy, pituitary tumours or prior pituitary irradiation, and pregnancy. Relative contraindications include pre-existing diabetes, significant cardiovascular disease, and chronic oedematous conditions. Each of these represents a context where known adverse effects carry greater clinical consequence.

References

[1]  Falutz J, et al. “Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients with Abdominal Fat Accumulation.” N Engl J Med. 2007;357(23):2349–2359.

[2]  Falutz J, et al. “Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV.” N Engl J Med. 2010;363(23):2249–2250.

[3]  Dhillon S. “Tesamorelin: A Review of its Use in the Management of HIV-associated Lipodystrophy.” Drugs. 2011;71(8):1071–1091.

[4]  Grunfeld C, et al. “Tesamorelin Suppresses Excess Visceral Adipose Tissue in HIV-Infected Patients: Primary Results of a Randomised, Double-Blind, Placebo-Controlled Trial.” J Acquir Immune Defic Syndr. 2010;53(3):311–322.

[5]  Stanley TL, et al. “Glucose Metabolism in HIV-infected Patients After Tesamorelin.” J Acquir Immune Defic Syndr. 2012;61(1):21–27.

[6]  Falutz J, et al. “Long-Term Safety and Effects of Tesamorelin, a Growth Hormone-Releasing Factor Analogue, in HIV-Infected Patients with Abdominal Fat Accumulation.” AIDS. 2008;22(14):1719–1728.

[7]  Yu H, Rohan T. “Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression.” J Natl Cancer Inst. 2000;92(18):1472–1489.

[8]  US Food and Drug Administration. “EGRIFTA (Tesamorelin) Prescribing Information.” FDA. 2010; updated 2019.

[9]  Falutz J, et al. “Effects of Tesamorelin on Cardiovascular Risk Markers in HIV-Infected Patients.” AIDS. 2014;28(7):989–999.

[10]  Sigalos JT, Pastuszak AW. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sex Med Rev. 2018;6(1):45–53.

[11]  Baker LD, et al. “Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults.” Arch Neurol. 2012;69(11):1420–1429.

[12]  Duron E, Hanon O. “Vascular Risk Factors, Cognitive Decline, and Dementia.” Vasc Health Risk Manag. 2008;4(2):363–381.

[13]  Falutz J, et al. “Visceral Adipose Tissue After Tesamorelin Discontinuation.” J Acquir Immune Defic Syndr. 2012;59(5):e89–e92.

[14]  Hazra A, et al. “Long-term Safety of Tesamorelin in HIV-Associated Lipodystrophy.” Expert Opin Drug Saf. 2016;15(6):855–863.

[15]  Colao A, et al. “Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management.” Endocr Rev. 2004;25(1):102–152.

Disclaimer: This article is intended for informational and educational purposes only. All content is drawn from peer-reviewed clinical research and published trial data. Nothing in this article constitutes medical advice, a treatment recommendation, or personal use guidance of any kind. Always consult a qualified healthcare professional before making any medical or health-related decisions.